1-7 of 7
Matt Coffey
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies

Christianne Groeneveldt, Priscilla Kinderman, Lisa Griffioen, Olivia Rensing, Camilla Labrie, Diana J.M. van den Wollenberg, Rob C. Hoeben, Matt Coffey, Houra Loghmani, Els M.E. Verdegaal, Marij J.P. Welters, Sjoerd H. van der Burg, Thorbald van Hall, Nadine van Montfoort
Journal: Cancer Immunology Research
Cancer Immunol Res (2024) 12 (3): 334–349.
https://doi.org/10.1158/2326-6066.CIR-23-0480
Published: 04 March 2024
View articletitled, Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies
Open the PDF for Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies in another window
Includes: Supplementary data
Journal Articles

Abstract B033: Multiplex analysis of the tumor immune microenvironment during treatment with atezolizumab/pelareorep/letrozole reveals novel immune-tumor interactions

Homa Dadrastoussi, Julian Olea, Eduardo Fernandez Hernandez, Hugo Lara Martinez, Kaijin Wu, Houra Loghmani, Thomas Heineman, Richard Trauger, Matt Coffey, Akil Merchant, Kevin Kelly
Journal: Cancer Immunology Research
Cancer Immunol Res (2023) 11 (12_Supplement): B033.
https://doi.org/10.1158/2326-6074.TUMIMM23-B033
Published: 01 December 2023
View articletitled, Abstract B033: Multiplex analysis of the tumor immune microenvironment during treatment with atezolizumab/pelareorep/letrozole reveals novel immune-tumor interactions
Journal Articles

Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment

Laura Evgin, Amanda L. Huff, Timothy Kottke, Jill Thompson, Amy M. Molan, Christopher B. Driscoll, Matthew Schuelke, Kevin G. Shim, Phonphimon Wongthida, Elizabeth J. Ilett, Karen Kaluza Smith, Reuben S. Harris, Matt Coffey, Jose S. Pulido, Hardev Pandha, Peter J. Selby, Kevin J. Harrington, Alan Melcher, Richard G. Vile
Journal: Cancer Immunology Research
Cancer Immunol Res (2019) 7 (5): 828–840.
https://doi.org/10.1158/2326-6066.CIR-18-0013
Published: 01 May 2019
View articletitled, Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
Open the PDF for Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment in another window
Includes: Supplementary data
Journal Articles

Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence

Tim Kottke, Laura Evgin, Kevin G. Shim, Diana Rommelfanger, Nicolas Boisgerault, Shane Zaidi, Rosa Maria Diaz, Jill Thompson, Elizabeth Ilett, Matt Coffey, Peter Selby, Hardev Pandha, Kevin Harrington, Alan Melcher, Richard Vile
Journal: Cancer Immunology Research
Cancer Immunol Res (2017) 5 (11): 1029–1045.
https://doi.org/10.1158/2326-6066.CIR-17-0175
Published: 31 October 2017
View articletitled, Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence
Open the PDF for Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence in another window
Journal Articles

Abstract B082: Reovirus treated NK cells exhibit enhanced cetuximab mediated antibody- dependent cellular cytotoxicity against colorectal cancer cell lines

Xing Zhao, Narendiran Rajasekaran, Cariad Chester, Atsushi Yonezawa, Suparna Dutt, Matt Coffey, Holbrook Kohrt
Journal: Cancer Immunology Research
Cancer Immunol Res (2016) 4 (1_Supplement): B082.
https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR15-B082
Published: 03 January 2016
View articletitled, Abstract B082: Reovirus treated NK cells exhibit enhanced cetuximab mediated antibody- dependent cellular cytotoxicity against colorectal cancer cell lines
Journal Articles

Abstract B88: Combination therapy of reovirus and checkpoint inhibition

Shane Zaidi, Kevin Shim, Karishma Rajani, Rosa Diaz, Elizabeth Ilett, Timothy Kottke, Jill Thompson, Peter Selby, Kevin Harrington, Hardev Pandha, Alan Melcher, Matt Coffey, Richard Vile
Journal: Cancer Immunology Research
Cancer Immunol Res (2015) 3 (10_Supplement): B88.
https://doi.org/10.1158/2326-6074.TUMIMM14-B88
Published: 09 October 2015
View articletitled, Abstract B88: Combination therapy of reovirus and checkpoint inhibition
Journal Articles

Abstract A49: Systemic oncolytic reovirus for the treatment of primary and secondary brain tumors

Adel Jebar, Liz Ilett, Tim Kottke, Emma West, Karen Scott, Simon Thomson, Matt Coffey, Gerard Nuovo, Susan Short, Richard Vile, Alan Melcher
Journal: Cancer Immunology Research
Cancer Immunol Res (2015) 3 (10_Supplement): A49.
https://doi.org/10.1158/2326-6074.TUMIMM14-A49
Published: 09 October 2015
View articletitled, Abstract A49: Systemic oncolytic reovirus for the treatment of primary and secondary brain tumors